AM Rx Review

AM Rx in one sentence: a Zealthy-operated platform with real legal baggage

AM Rx (getamrx.com) sells access to both compounded and brand-name GLP-1 weight-loss medications, and on paper its menu looks broad — compounded semaglutide, plus all four big brand drugs (Ozempic, Wegovy, Zepbound, Mounjaro) with insurance coordination. But the single most important fact about AM Rx is not its pricing. It is operated by FitRX, LLC — the same company behind Zealthy and FitRx — and that corporate family is currently dealing with an active FTC/DOJ lawsuit, two FDA warning letters, and a Novo Nordisk false-advertising suit. We cannot recommend it without putting those front and center, and neither should you sign up without reading them.

How the money actually works (and why it's confusing)

AM Rx does not charge one simple price. There are two separate bills. First, a recurring AM Rx membership: a standard monthly subscription with a heavily discounted first month at $39 (advertised as a limited-time offer, roughly ninety-six dollars off the standard rate). That membership renews every month unless you cancel. Second, the medication itself, billed on top of the membership. Compounded semaglutide lands at roughly a hundred and fifty dollars a month — but only when you commit to a quarterly purchase. Brand-name GLP-1s can drop to as low as the mid-twenties per month, but that figure depends entirely on your insurance actually covering the drug; without coverage the real cost is far higher.

The catch worth underlining: the teaser first-month membership price and the headline medication prices are two different charges. The category median runs around $170 a month, so AM Rx's medication-only numbers can look competitive — until you add the separate, auto-renewing membership fee back on. The recurring-subscription model is, notably, exactly the practice at the center of the FTC/DOJ complaint.

The medications and how they're dispensed

On the compounded side you get semaglutide as a weekly injection, with supplies included and 24/7 access to licensed providers described as part of the plan. On the brand side, AM Rx positions itself as an insurance-coordination service — its team works with your plan to get Ozempic, Wegovy, Zepbound, or Mounjaro (the latter two being tirzepatide) approved and dispensed through a pharmacy. Video and asynchronous consultations are both available, and HSA/FSA payment is accepted.

One thing we could not verify: who actually compounds the medication. There is no named pharmacy partner, no LegitScript certification, no PCAB accreditation, and — critically — no FDA compounding disclaimer published on the site. For a service selling compounded drugs, that absence is a meaningful gap, not a rounding error.

What sets AM Rx apart — and not in a good way

Most providers we review differentiate on price, formulation, or support quality. AM Rx's defining feature is its regulatory record, so here is the honest list:

• Two FDA warning letters. FitRX LLC was cited in September 2025 for misbranding compounded GLP-1 products, then again on February 20, 2026 under Sections 502(a) and 502(bb) of the FD&C Act — the labels named FitRx as the compounder when it was not.
• An active FTC/DOJ lawsuit over deceptive billing and subscription (ROSCA) practices — the same kind of recurring-charge model AM Rx uses.
• A Novo Nordisk false-advertising lawsuit filed in August 2025.
• A BBB D- rating for parent Zealthy, against 2,370-plus complaints.
• A Trustpilot score of 2.0 out of 5, with about 85% one-star reviews citing billing disputes and support that customers couldn't reach.

It's also worth knowing that the AM Rx and Zealthy storefronts are visibly merging — the homepage still renders 'Your Zealthy treatment plan starts here,' the navigation uses Zealthy code, and the app-download button points to a Zealthy link. The founder, Kyle Robertson, also founded Cerebral. None of this is hidden, but none of it inspires confidence either.

Who might consider it — and who should walk away

There is a narrow case for AM Rx: if you have solid insurance coverage for a brand-name GLP-1 and you want a service to handle the prior-authorization legwork for you, the brand insurance-coordination angle is the one genuinely useful thing here. Even then, watch the membership auto-renewal closely and document every charge.

Who should skip it: anyone buying compounded semaglutide hoping for clear pharmacy provenance, anyone uncomfortable with auto-renewing subscriptions, and frankly anyone who would rather not hand payment details to a company in the middle of an FTC/DOJ action. The complaint pattern — surprise charges and unreachable support — is exactly what you'd want to avoid, and it's well documented.

Trust and medical oversight

AM Rx advertises video visits with providers averaging 10-plus years of experience, and that clinical layer may well be real. But our verification confidence in the operation as a whole is low. With two FDA warning letters on file, no accreditation, no disclosed compounding pharmacy, and no published state-availability list, the safeguards we look for in our scoring methodology are largely missing. We don't dispute that some patients get their medication and do fine; we do dispute that the oversight here is reassuring.

Bottom line

AM Rx's prices, taken in isolation, aren't outrageous — compounded semaglutide near the category middle once you account for the quarterly commitment, and brand drugs cheap if insurance plays along. But you can't take the prices in isolation. The recurring membership, the missing pharmacy transparency, the dismal review scores, and above all the stack of federal actions against the parent company make this a provider to approach with real caution. If you proceed, do it with eyes open, insurance in hand, and a calendar reminder to check your statements.

Shopping around? Telos Rx ($49/month) and bmiMD ($99/month) are the nearest alternatives to AM Rx in our rankings.